Patent · US Active

Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease

US11505619B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

CSL LIMITED · AU

Inventors

Malgorzata Wygrecka · Gießen, DE
Marc Nolte · Marburg, DE
Con Panousis · Melbourne, AU

Key dates

Filing date	Dec 14, 2018
Grant date	Nov 22, 2022
Priority date	—
Expiry date	Dec 14, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.